Abstract
Polar lipids and various surfactants exhibit rich phase behavior depending on the composition of the lipids and the physicochemical conditions. Lamellar (Lα), hexagonal (Inverted [HII]) and normal or inverted cubic (bicontinuous or micellar) structures are some of the most common lyotropic liquid crystalline phases. Hexosomes are the reverse hexagonal phases comprised of hexagonally close-packed infinite water layers covered by surfactants monolayer. Hexosomes (dispersed HII phases) due to their special structural properties have potential to be used as alternative delivery vehicle for pharmaceuticals. Biologically active molecules can either be accommodated within the aqueous domains or can be directly coupled to the lipid hydrophobic moieties oriented radially outwards from the centre of the water rods. Due to these special properties of hexosomes, they are used to improve solubility of poorly water soluble drugs and to transport therapeutic peptides and proteins by oral, transdermal, and parenteral routes. This article includes various methods of preparation of hexosomes and their application in drug delivery through various routes.
Keywords: Hexosomes, reverse hexagonal phases, transdermal, parenteral route
Current Drug Delivery
Title: Hexosomes: A Novel Drug Delivery System
Volume: 7 Issue: 1
Author(s): Rajashree Hirlekar, Sunilkumar Jain, Mayank Patel, Harshal Garse and Vilasrao Kadam
Affiliation:
Keywords: Hexosomes, reverse hexagonal phases, transdermal, parenteral route
Abstract: Polar lipids and various surfactants exhibit rich phase behavior depending on the composition of the lipids and the physicochemical conditions. Lamellar (Lα), hexagonal (Inverted [HII]) and normal or inverted cubic (bicontinuous or micellar) structures are some of the most common lyotropic liquid crystalline phases. Hexosomes are the reverse hexagonal phases comprised of hexagonally close-packed infinite water layers covered by surfactants monolayer. Hexosomes (dispersed HII phases) due to their special structural properties have potential to be used as alternative delivery vehicle for pharmaceuticals. Biologically active molecules can either be accommodated within the aqueous domains or can be directly coupled to the lipid hydrophobic moieties oriented radially outwards from the centre of the water rods. Due to these special properties of hexosomes, they are used to improve solubility of poorly water soluble drugs and to transport therapeutic peptides and proteins by oral, transdermal, and parenteral routes. This article includes various methods of preparation of hexosomes and their application in drug delivery through various routes.
Export Options
About this article
Cite this article as:
Hirlekar Rajashree, Jain Sunilkumar, Patel Mayank, Garse Harshal and Kadam Vilasrao, Hexosomes: A Novel Drug Delivery System, Current Drug Delivery 2010; 7 (1) . https://dx.doi.org/10.2174/156720110790396526
DOI https://dx.doi.org/10.2174/156720110790396526 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry L9 Orthogonal Design Assisted Formulation and Evaluation of Chitosanbased Buccoadhesive Films of Miconazole Nitrate
Current Drug Delivery Gold Nanoparticle Based Systems in Genetics
Current Pharmacogenomics Pharmacophore Generation and 3D-QSAR of Novel 2-(quinazolin-4- ylamino)-[1,4] Benzoquinone Derivatives as VEGFR-2 Inhibitors
Letters in Drug Design & Discovery Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Novel Insights Into c-Src
Current Pharmaceutical Design CD147 Interacts with NDUFS6 in Regulating Mitochondrial Complex I Activity and the Mitochondrial Apoptotic Pathway in Human Malignant Melanoma Cells
Current Molecular Medicine Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials The ACE Insertion/Deletion Polymorphism and Risk of Cancer, a Review and Meta-Analysis of the Literature
Current Cancer Drug Targets Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other Disorders
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Anti-Cancer Agents in Medicinal Chemistry Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Current Pharmaceutical Design Physiologically Based Mathematical Models to Optimize Therapies Against Metastatic Colorectal Cancer: A Mini-Review
Current Pharmaceutical Design PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets